{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:01:34Z","timestamp":1792364494150,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI150917-01"],"award-info":[{"award-number":["R01 AI150917-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rift Valley fever (RVF) is a mosquito-borne zoonosis endemic to Africa and the Arabian Peninsula, which causes large outbreaks among humans and ruminants. Single dose vaccinations using live-attenuated RVF virus (RVFV) support effective prevention of viral spread in endemic countries. Due to the segmented nature of RVFV genomic RNA, segments of vaccine strain-derived genomic RNA could be incorporated into wild-type RVFV within co-infected mosquitoes or animals. Rationally designed vaccine candidate RVax-1 displays protective epitopes fully identical to the previously characterized MP-12 vaccine. Additionally, all genome segments of RVax-1 contribute to the attenuation phenotype, which prevents the formation of pathogenic reassortant strains. This study demonstrated that RVax-1 cannot replicate efficiently in orally fed <jats:italic>Aedes aegypti<\/jats:italic> mosquitoes, while retaining strong immunogenicity and protective efficacy in an inbred mouse model, which were indistinguishable from the MP-12 vaccine. These findings support further development of RVax-1 as the next generation MP-12-based vaccine for prevention of Rift Valley fever in humans and animals.<\/jats:p>","DOI":"10.1038\/s41541-022-00536-3","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:04:55Z","timestamp":1663769095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-2783","authenticated-orcid":false,"given":"Tetsuro","family":"Ikegami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-4645","authenticated-orcid":false,"given":"Eduardo","family":"Jurado-Cobena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-9270","authenticated-orcid":false,"given":"Cigdem","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Kalveram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Juelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-6797","authenticated-orcid":false,"given":"Allen T.","family":"Esterly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnavi R.","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanan","family":"Thangamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-8960","authenticated-orcid":false,"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"536_CR1","doi-asserted-by":"publisher","first-page":"e0009852","DOI":"10.1371\/journal.pntd.0009852","volume":"16","author":"KN Gerken","year":"2022","unstructured":"Gerken, K. N. et al. Paving the way for human vaccination against Rift Valley fever virus: a systematic literature review of RVFV epidemiology from 1999 to 2021. PLoS Negl. Trop. Dis. 16, e0009852 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"536_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/vetres\/2010033","volume":"41","author":"M Pepin","year":"2010","unstructured":"Pepin, M., Bouloy, M., Bird, B. H., Kemp, A. & Paweska, J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41, 61 (2010).","journal-title":"Vet. Res."},{"key":"536_CR3","unstructured":"Swanepoel, R. & Coetzer, J. A. W. in Infectious Diseases of Livestock with Special Reference to Southern Africa 2nd edn (eds Coetzer J. A. W. & Tustin R. C.) 1037\u20131070 (Oxford University Press, Cape Town, 2004)."},{"key":"536_CR4","unstructured":"C. D. C. Rift Valley fever outbreak\u2013Kenya, November 2006\u2013January 2007. MMWR Morb. Mortal. Wkly Rep. 56, 73\u201376 (2007)."},{"key":"536_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"536_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird, B. H., Ksiazek, T. G., Nichol, S. T. & Maclachlan, N. J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234, 883\u2013893 (2009).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"536_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12985-016-0573-8","volume":"13","author":"HJ Ly","year":"2016","unstructured":"Ly, H. J. & Ikegami, T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virol. J. 13, 118 (2016).","journal-title":"Virol. J."},{"key":"536_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/v8060174","volume":"8","author":"JD Wuerth","year":"2016","unstructured":"Wuerth, J. D. & Weber, F. Phleboviruses and the Type I interferon response. Viruses 8, 174 (2016).","journal-title":"Viruses"},{"key":"536_CR9","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/emi.2014.71","volume":"3","author":"F Kreher","year":"2014","unstructured":"Kreher, F. et al. The Rift Valley fever accessory proteins NSm and P78\/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts. Emerg. Microbes Infect. 3, e71 (2014).","journal-title":"Emerg. Microbes Infect."},{"key":"536_CR10","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1128\/JVI.01238-07","volume":"81","author":"S Won","year":"2007","unstructured":"Won, S., Ikegami, T., Peters, C. J. & Makino, S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81, 13335\u201313345 (2007).","journal-title":"J. Virol."},{"key":"536_CR11","doi-asserted-by":"publisher","first-page":"e2670","DOI":"10.1371\/journal.pntd.0002670","volume":"8","author":"RC Kading","year":"2014","unstructured":"Kading, R. C. et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 8, e2670 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"536_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","author":"H Caplen","year":"1985","unstructured":"Caplen, H., Peters, C. J. & Bishop, D. H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66, 2271\u20132277 (1985).","journal-title":"J. Gen. Virol."},{"key":"536_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","volume":"34","author":"PR Pittman","year":"2016","unstructured":"Pittman, P. R. et al. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. Vaccine 34, 424\u2013429 (2016).","journal-title":"Vaccine"},{"key":"536_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","volume":"34","author":"PR Pittman","year":"2016","unstructured":"Pittman, P. R. et al. Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. Vaccine 34, 523\u2013530 (2016).","journal-title":"Vaccine"},{"key":"536_CR15","first-page":"31","volume":"114","author":"RE Hill Jr","year":"2003","unstructured":"Hill, R. E. Jr et al. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States. Dev. Biol. (Basel) 114, 31\u201352 (2003).","journal-title":"Dev. Biol. (Basel)"},{"key":"536_CR16","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1128\/JVI.02241-15","volume":"90","author":"S Nishiyama","year":"2016","unstructured":"Nishiyama, S., Lokugamage, N. & Ikegami, T. The L-, M- and S-segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype. J. Virol. 90, 3735\u201337644 (2016).","journal-title":"J. Virol."},{"key":"536_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0021-9","volume":"2","author":"N Lokugamage","year":"2017","unstructured":"Lokugamage, N. & Ikegami, T. Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells. npj Vaccines 2, 20 (2017).","journal-title":"npj Vaccines"},{"key":"536_CR18","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","volume":"89","author":"T Ikegami","year":"2015","unstructured":"Ikegami, T. et al. Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments. J. Virol. 89, 7262\u20137276 (2015).","journal-title":"J. Virol."},{"key":"536_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/infdis\/jir249","volume":"204","author":"JC Morrill","year":"2011","unstructured":"Morrill, J. C. & Peters, C. J. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. J. Infect. Dis. 204, 229\u2013236 (2011).","journal-title":"J. Infect. Dis."},{"key":"536_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1128\/CVI.00114-15","volume":"22","author":"MM Miller","year":"2015","unstructured":"Miller, M. M. et al. Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep. Clin. Vaccin. Immunol. 22, 930\u2013937 (2015).","journal-title":"Clin. Vaccin. Immunol."},{"key":"536_CR21","doi-asserted-by":"publisher","unstructured":"Campbell, C. L. et al. Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes. Transbound Emerg. Dis. https:\/\/doi.org\/10.1111\/tbed.14415 (2021).","DOI":"10.1111\/tbed.14415"},{"key":"536_CR22","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3201\/eid1712.111035","volume":"17","author":"AA Grobbelaar","year":"2011","unstructured":"Grobbelaar, A. A. et al. Molecular epidemiology of Rift Valley fever virus. Emerg. Infect. Dis. 17, 2270\u20132276 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"536_CR23","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.jvacx.2020.100060","volume":"5","author":"TP Monath","year":"2020","unstructured":"Monath, T. P. et al. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF target product profile. Vaccin. X 5, 100060 (2020).","journal-title":"Vaccin. X"},{"key":"536_CR24","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1016\/j.vaccine.2017.10.036","volume":"35","author":"HJ Ly","year":"2017","unstructured":"Ly, H. J. et al. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain. Vaccine 35, 6634\u20136642 (2017).","journal-title":"Vaccine"},{"key":"536_CR25","doi-asserted-by":"publisher","first-page":"e02004","DOI":"10.1128\/JVI.02004-20","volume":"95","author":"T Ikegami","year":"2021","unstructured":"Ikegami, T. Development of a simian RNA polymerase I promoter-driven reverse genetics for the rescue of recombinant Rift Valley fever virus from vero cells. J. Virol. 95, e02004\u2013e02020 (2021).","journal-title":"J. Virol."},{"key":"536_CR26","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1128\/JVI.00476-06","volume":"80","author":"S Won","year":"2006","unstructured":"Won, S., Ikegami, T., Peters, C. J. & Makino, S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J. Virol. 80, 8274\u20138278 (2006).","journal-title":"J. Virol."},{"key":"536_CR27","doi-asserted-by":"publisher","first-page":"e725","DOI":"10.1371\/journal.pntd.0000725","volume":"4","author":"N Bhardwaj","year":"2010","unstructured":"Bhardwaj, N., Heise, M. T. & Ross, T. M. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4, e725 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"536_CR28","first-page":"197","volume":"92","author":"BS Niklasson","year":"1984","unstructured":"Niklasson, B. S., Meadors, G. F. & Peters, C. J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol. Microbiol Immunol. Scand. C 92, 197\u2013200 (1984).","journal-title":"Acta Pathol. Microbiol Immunol. Scand. C"},{"key":"536_CR29","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1128\/JVI.00337-13","volume":"87","author":"KA Dodd","year":"2013","unstructured":"Dodd, K. A., McElroy, A. K., Jones, M. E., Nichol, S. T. & Spiropoulou, C. F. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T Cell and virus-specific antibody responses. J. Virol. 87, 6161\u20136171 (2013).","journal-title":"J. Virol."},{"key":"536_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/vaccines8010082","volume":"8","author":"E Lopez-Gil","year":"2020","unstructured":"Lopez-Gil, E. et al. MVA vectored vaccines encoding Rift Valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses. Vaccines 8, 82 (2020).","journal-title":"Vaccines"},{"key":"536_CR31","doi-asserted-by":"publisher","first-page":"e0189250","DOI":"10.1371\/journal.pone.0189250","volume":"12","author":"T Ikegami","year":"2017","unstructured":"Ikegami, T. et al. Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLoS One 12, e0189250 (2017).","journal-title":"PLoS One"},{"key":"536_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1099\/vir.0.051250-0","volume":"94","author":"SV Indran","year":"2013","unstructured":"Indran, S. V. et al. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. J. Gen. Virol. 94, 1441\u20131450 (2013).","journal-title":"J. Gen. Virol."},{"key":"536_CR33","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","volume":"21","author":"JC Morrill","year":"2003","unstructured":"Morrill, J. C. & Peters, C. J. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21, 2994\u20133002 (2003).","journal-title":"Vaccine"},{"key":"536_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1017\/S0022172400062434","volume":"95","author":"KJ Linthicum","year":"1985","unstructured":"Linthicum, K. J., Davies, F. G., Kairo, A. & Bailey, C. L. Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya. J. Hyg. 95, 197\u2013209 (1985).","journal-title":"J. Hyg."},{"key":"536_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","volume":"61","author":"KJ Linthicum","year":"2016","unstructured":"Linthicum, K. J., Britch, S. C. & Anyamba, A. Rift Valley fever: an emerging mosquito-borne disease. Annu Rev. Entomol. 61, 395\u2013415 (2016).","journal-title":"Annu Rev. Entomol."},{"key":"536_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/jmedent\/45.1.102","volume":"45","author":"MJ Turell","year":"2008","unstructured":"Turell, M. J. et al. Vector competence of selected African mosquito (Diptera: Culicidae) species for Rift Valley fever virus. J. Med Entomol. 45, 102\u2013108 (2008).","journal-title":"J. Med Entomol."},{"key":"536_CR37","doi-asserted-by":"publisher","first-page":"e1639","DOI":"10.1371\/journal.pntd.0001639","volume":"6","author":"MB Crabtree","year":"2012","unstructured":"Crabtree, M. B. et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and\/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6, e1639 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"536_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","volume":"47","author":"N Ito","year":"2003","unstructured":"Ito, N. et al. Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol Immunol. 47, 613\u2013617 (2003).","journal-title":"Microbiol Immunol."},{"key":"536_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res Methods"},{"key":"536_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25\u2009years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"536_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00536-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:06:45Z","timestamp":1663769205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00536-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00536-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"18 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.I. has a pending patent for RVax-1 vaccine submitted through UTMB (US17\/067,144). Authors E.J-C., C.A., J.K.S., L.Z., B.K., T.L.J., A.T.E., J.R.B., S.T., and A.N.F. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}